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Abstract
Background: Physical exercise has become a cornerstone of management of chronic obstructive pulmonary
disease (COPD) because it leads to clinically relevant improvements of exercise capacity and health-related
quality of life (HRQL). Despite the scarcity of randomised trials directly comparing exercise protocols, current
guidelines recommend high intensity continuous exercise for lower extremities as the probably most effective
exercise modality. However, for patients admitted to inpatient respiratory rehabilitation programmes, it is often
difficult to initiate such an exercise programme because they are severely limited by dyspnoea and leg fatigue and
therefore unable to perform continuous exercise at higher intensities and for periods longer than 30 minutes.
Interval exercise may be an attractive alternative for these COPD patients because it allows high intensity exercise
with recovery periods. The aim of this study is to assess if interval exercise compared to high intensity continuous
exercise is not of inferior effectiveness in terms of HRQL and exercise capacity improvements but associated with
better exercise tolerance in patients with moderate to severe COPD at the beginning of a respiratory
rehabilitation.
Methods/Design: We will assign patients with moderately severe to severe COPD to either continuous
exercise or interval exercise using a stratified randomisation. Patients will follow 12–15 exercise sessions during
a comprehensive inpatient respiratory rehabilitation. Primary end point for effectiveness is HRQL as measured
by the Chronic Respiratory Questionnaire (CRQ) two weeks after the end of rehabilitation and secondary
endpoints include additional clinical outcomes such as functional exercise capacity, other HRQL measures,
patients' experience of physical exercise as well as physiological measures of the effects of physical exercise such
as cardiopulmonary exercise testing. Including expected drop-outs, we will need 52 patients per group to show
differences corresponding to the minimal clinically important difference of the CRQ. Outcome assessors and
investigators involved in data analysis will be blinded to group assignment until analyses have been carried out.
Discussion: Clinicians and the scientific community need evidence on the benefits and tolerance of exercise
protocols available in clinical practice. The proposed trial will provide important and needed data on interval and
continuous exercise for decision making in clinical practice.
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Background
Impaired exercise capacity, dyspnoea and reduced health-
related quality of life (HRQL) are common complaints of
patients with chronic obstructive pulmonary disease
(COPD). A major exercise-limiting factor in COPD is
peripheral muscle dysfunction characterised by atrophic
muscles and reduced fatigue resistance due morphologi-
cal and metabolic alterations of peripheral muscles[1] As
much as 70% of COPD patients may be affected by
peripheral muscle dysfunction.[2]
Respiratory rehabilitation with physical exercise improves
exercise capacity and HRQL.[3] Although physical exer-
cise is a mandatory component of respiratory rehabilita-
tion programmes[4,5], there is an ongoing debate about
what type of exercise at which exercise intensity patients
should perform.[1,6] There is substantial variation in
exercise protocols used in practice[7] as well as in clinical
trials[3]. Current guidelines recommend continuous exer-
cise at high intensity for lower extremities[4,5] because a
study indicated that high intensity may be more effective
than low or moderate intensity.[8]
However, data on high intensity continuous exercise
come from a trial that included 19 patients with mild
COPD who were able to exercise for 45 minutes five times
per week during an outpatient programme.[8] For
patients who need to be admitted to inpatient pro-
grammes because of more severe COPD and/or unstable
health state, it is difficult to perform high intensity exer-
cise and exercise sessions longer than 30 minutes because
they are limited by dyspnoea and leg fatigue. Less than
20% may be able to sustain high intensity continuous
exercise throughout the whole rehabilitation pro-
gramme[9] To find a realistically tolerable exercise pro-
gramme for these patients, who often initiate exercise
programmes for the first time, is challenging.
A solution to this dilemma may represent interval exer-
cise[6] where patients exercise alternatively at high inten-
sity and at low intensity, which allows short periods of
recovery. Consequently, interval training may be better
tolerated than high intensity continuous training. In addi-
tion, patients may be able to achieve a greater training
load during the relatively short exercise sessions they can
sustain.
Patients and clinicians will accept interval exercise to treat
peripheral muscular dysfunction in COPD only if it is not
of inferior effectiveness compared with continuous exer-
cise and if it is indeed associated with better compliance
resulting from less dyspnoea and leg fatigue during exer-
cise. There is limited evidence from three randomised
controlled trials comparing interval exercise and continu-
ous exercise.[10-12] A summary of these trials can be
found in table 1.
The studies indicated that both interval and continuous
training improved exercise capacity, dyspnoea and HRQL
and showed insignificant differences between interval and
continuous exercise. However, insignificant differences do
not allow concluding that interval or continuous are of
clinically equivalent effectiveness[13] These trials were
too small to show clinical equivalence or non-inferiority
and they did not provide evidence on the tolerance of
these two exercise modalities. From a methodological
point of view, the trial had several shortcomings because,
for example, they did not provide details on concealment
of random allocation or blinding of outcome assessors. In
addition, in the trial with an inpatient rehabilitation.[10],
patients of the interval exercise group had a mixed inter-
vention (3 days of interval and 2 days of continuous exer-
cise per week) so that differences can hardly be attributed
to different interventions if they are detected at all.
The investigators did not use steep ramp tests to deter-
mine exercise loads but normal incremental exercise tests.
For interval exercise, muscle strength and anaerobic
capacity is relevant because of the short high intensity
intervals, but this is not measured by normal incremental
exercise tests. In addition, training load tolerated during
interval exercise may be underestimated when normal
incremental exercise tests are used.[14]
Exercise tests to establish training intensity should con-
sider the exercise mode. Meyer et al. studied interval exer-
cise in several studies [14-16] in patients with chronic
heart failure who show similar patterns of physical decon-
ditioning in terms of clinical manifestation as well as mor-
phological and metabolic abnormalities [17-19] Meyer et
al. used a steep ramp test to determine short time muscu-
lar maximum exercise capacity[14], which reflects muscle
strength and anaerobic capacity, both relevant for interval
exercise.
Meyer et al. also assessed different ratios of work/recovery
phases (1:2; 1:4 and 1:6) and found that with these ratios
and relatively short phases of high intensity exercise (10–
30 seconds), lactate did not accumulate presumably
because of lactate elimination during the recovery
phases.[14] Interval exercise with these ratios was there-
fore recommended as high intensity aerobic exercise
modes for patients who do not sustain continuous
exercise.
Because of the scarcity of evidence on the comparative
effectiveness of interval exercise for COPD patients, addi-
tional trials are needed.[1,6] Our primary objective is to
assess if interval exercise is not of inferior effectivenessBMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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compared to continuous exercise of high intensity to
improve HRQL and exercise capacity in patients with
moderately severe to severe COPD and the secondary
objective is to evaluate if interval exercise is better toler-
ated by COPD patients.
Methods
Study design (see figure 1)
All consecutive patients admitted to a teaching rehabilita-
tion clinic for an inpatient respiratory rehabilitation
(Klinik Barmelweid, Barmelweid, Switzerland) will be
assessed for study eligibility by senior staff physicians. If
patients are deemed eligible after exercise testing, which is
part of the usual rehabilitation program, senior physicians
will inform patients about the study orally and in writing.
If patients are willing to participate and provide written
informed consent they will be randomly assigned to respi-
ratory rehabilitation with either interval or high intensity
continuous exercise. Both groups will perform 12–15
exercise sessions and follow the rest of the rehabilitation
programme. Follow-up assessments will be done during,
at the end of the rehabilitation programme as well as two
and twelve weeks afterwards when patients are back in
their home environment.
The Ethikkommission of the Kantonsspital Aarau, Aargau,
Switzerland, has approved the study protocol.
Patients
We defined the following in- and exclusion criteria:
Patients with COPD as defined by FEV1/FVC < 70% pre-
dicted, FEV1 < 50 % predicted after bronchodilation, with
or without chronic symptoms (cough, sputum produc-
tion) corresponding to a GOLD (Global Initiative for
Chronic Obstructive Lung Disease) stage III-IV[20] and
German as first or daily language. Exclusion criteria are
arrhythmia (atrial flutter and fibrillation, ventricular tach-
ycardia, premature beats > 8 per minute), ischemia during
Table 1: Trials on interval exercise in patients with COPD
Population Exercise protocols and 
rehabilitation program
Main results
Coppoolse 1999 [10] 21 stable male COPD patients (mean 
age 65 years, FEV1 36.8% predicted)
Group 1: CT ergometer cycling at 
60% of Wmax
Group 2: IT ergometer cycling at 90% 
of Wmax (1 min) and 45% of Wmax (2 
min) 3 days/week plus CT ergometer 
cycling at 60% of Wmax 2 days/week
8 weeks inpatient rehabilitation with 5 
exercise sessions per week of 30 min. 
No additional physical exercise.
Significant increase of VO2 and 
decrease of minute ventilation with 
CT but no changes with IT.
Significant increase of Wmax and 
decrease of leg pain during exercise 
with IT but not with CT.
Only significant differences between 
CT and IT for VO2/Wmax favouring 
CT. 91% of patients with CT and 90% 
of patients with IT completed the 
exercise program.
Vogiatzis 2002 [11] 45 stable COPD patients (62% males, 
(mean age 65 years, FEV1 34.1% 
predicted)
Group 1: CT ergometer cycling at 
50% of Wmax weeks 1–4, at 60% 
weeks 5–8 and at 70% weeks 9–12
Group 2: IT ergometer cycling at 
100% of Wmax (30 sec) and 45% of 
Wmax (30 sec) weeks 1–4, at 120% 
weeks 5–8 and at 140% weeks 9–12
12 weeks outpatient rehabilitation 
with 2 exercise sessions per week of 
40 min. No additional physical 
exercise.
Significant improvements of CRQ 
scores and Wmax and reductions of 
minute ventilation during CWRT in 
both groups. No significant differences 
between groups.
Attendance rate for exercise sessions 
88% for CT and 90% for IT.
Kaelin 2001 [12] 19 stable COPD patients (89% males) 
(mean age 67 years, FEV1 26.9% 
predicted)
Group 1: CT walking on stepper (70 
steps/minute) or treadmill (1.5 miles/
hour). Increase of 1 MET every 2 
weeks
Group 2: IT walking on stepper (70 
steps/minute) or treadmill (1.5 miles/
hour) with active rest to ratio of 2:1. 
Increase of 1 MET every 2 weeks
6 weeks outpatient rehabilitation with 
3 exercise sessions per week of 10–30 
min. Additional resistance training and 
flexibility training.
Larger improvements of 6-minute 
walking distance with IT (80 meters) 
compared with CT (39 meters).
No data on compliance.
CT = Continuous training; IT = Interval training; CRQ = Chronic Respiratory Questionnaire Wmax = Maximum exercise capacity, measured by 
usual incremental exercise test; CWRT = Constant work rate test; VO2 = Maximum oxygen consumption MET = Metabolic equivalentBMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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Flow of the study from screening for eligible patients to the final outcome assessment Figure 1
Flow of the study from screening for eligible patients to the final outcome assessment.
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exercise testing, clinically decompensated Cor pulmonale
or heart failure, untreated neoplasia or neoplasia that
needed treatment within the previous two years, lung sur-
gery within the previous three months, orthopedic, rheu-
matologic, vascular or neurological disorders that inhibit
ergometer training, gymnastic or guided walking tours,
and patients unable to perform or complete the six-
minute walk test or the incremental cycle test
Randomisation
A third party not involved in the conduction of the trial
will provide online central randomisation (DatInf GmbH,
Tuebingen, Germany). A computerised 'minimisation'
procedure will be used to avoid chance baseline imbal-
ances in prognostically important variables[21] Minimi-
sation variables will be exercise capacity (< 300 or ≥  300
meters in six-minute walk test), the presence of affective
disorders (Hospital Anxiety Depression Scale scores < or ≥
8), status of COPD (unstable COPD = In- or outpatient
medical care in the last eight weeks due to exacerbation of
COPD versus stable COPD = no in- or outpatient medical
care in the last eight weeks due to exacerbation of COPD)
and the need for oxygen at rest (yes = long term home oxy-
gen therapy or paO2 < 55 mmHg or no = paO2 ≥  55
mmHg).
Every time the study coordinator has been informed
about an enrolled patients, he will enter the randomisa-
tion web site[22] enter the patient data required for ran-
domisation (patient identification and stratification
variables) and obtain group allocation. The study coordi-
nator will then inform responsible physical therapists
about group allocation. No other medical staff will have
knowledge about group allocation. The randomisation
provider will also send an e-mail to the study coordinator
for each randomised patient with details on randomisa-
tion. This will ensure correct verification of group alloca-
tion after data analysis.
Separating patient enrolment and baseline assessments
(physicians and physical therapists) from the randomisa-
tion procedure (study coordinator not involved in patient
enrolment or rehabilitation programme) will ensure con-
cealment of random allocation.
Interventions
The rehabilitation programme will start one day after
baseline assessments and study enrolment. Exercise ses-
sions and group lessons will take place five days a week
and will consist of daily cycle ergometer training, breath-
ing therapies (30 minutes per day), and guided walking of
15 to 30 minutes. Relaxation therapies (technique accord-
ing to Jacobson) take place twice a week, patient educa-
tion (information about COPD, coping strategies,
inhalation techniques) three times a week, smoking cessa-
tion advice once a week or more if needed. Apart from
physical exercise, the rehabilitation programme of
approximately three weeks will be identical for both
groups.
Group performing continuous exercise
The target workload for this group will be ≥  70% of the
maximum exercise capacity expressed in Watts and heart
rate achieved during the incremental cycle ergometer test.
Patients are usually not able to perform high intensity
continuous exercise from the beginning and have to adapt
to physical exercise. Physical therapists will increase train-
ing load as soon as possible to ≥  70% of the maximum
exercise capacity or as high as each individual patient tol-
erates. In each session (see figure 2), patients will have a
warm-up period of two minutes at 20% of maximum
exercise capacity, increase the exercise intensity within
two minutes to the target intensity, exercise for 20 min-
utes at high intensity and then have a decreasing period of
two minutes (gradual decrease from 70% to 0%). Pulse
oxymetry will be used to supervise patients during exer-
cise. If oxygen saturation falls below 90%, oxygen supple-
mentation will be provided to maintain ≥  90%.
If patients cannot sustain the workload because of per-
ceived dyspnoea or leg fatigue or because the heart rate
exceeds the limits determined during exercise testing,
physical therapists will let patients rest for one minute and
then resume exercise. If patients have to rest more than
twice per session, physical therapists will lower the work-
load by steps of 10% of baseline maximum exercise capac-
ity. In turn, if patients or physical therapists consider the
workload to be too low or if patients do not reach their
target heart rate at 70% of the maximum exercise capacity,
physical therapists will increase workload by steps of 10%
of maximum exercise capacity until patients and physical
therapists consider the workload to be appropriate or
until the target heart rate is reached.
Group performing interval exercise
Patients assigned to this group will perform a steep ramp
test to determine the short time muscular maximum exer-
cise capacity.[14] The steep ramp test is an incremental
cycle ergometer test where patients pedal unloaded for 2
minutes and then pedal with increments of 25 Watts every
10 seconds until they cannot maintain a pedaling fre-
quency above 50 per minute or above the heart rate limit
set by the normal incremental exercise test (which all
patients perform irrespective of group assignment). With
the steep ramp test measurement of muscular maximum
exercise capacity is possible because the tests lasts only for
30 to 120 seconds and patients are not limited by symp-
toms. Measuring muscular maximum exercise capacity is
important to set the exercise load for interval exerciseBMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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because the high intensity interval requires also muscle
strength beside overall exercise endurance.[14]
Patients should improve both endurance and muscle
strength during interval exercise because both are required
in daily activities. We therefore chose a work/recovery
ratio of 1:2 that prevents from high lactate accumula-
tion.[14] From short time maximum exercise capacity, we
will derive the initial work rate for interval exercise (in
Watts), which is set at 50% of the short time muscular
maximum exercise capacity as measured by the steep
ramp test. This workload corresponds in Watts
The upper graph shows the continuous exercise protocol for a patient who achieved a maximum exercise capacity of 100  Watts during a usual incremental exercise test Figure 2
The upper graph shows the continuous exercise protocol for a patient who achieved a maximum exercise capacity of 100 
Watts during a usual incremental exercise test. The lower graph shows the interval exercise protocol for a patient who 
achieved a short time muscular exercise capacity of 200 Watts during a steep ramp test.
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approximately to 90–100% of the workload as measured
by the normal incremental exercise test.[16].
Patients will start with exercise the day after the steep
ramp test. Patients will perform interval exercise for
twelve to fifteen sessions with a cycle ergometer. In each
session, they will have a warm up period of two minutes
at 20% of the short time maximum exercise capacity (fig-
ure 2). Then they exercise for 20 minutes at high intensity
intervals of 20 seconds at 50% and at low intensity inter-
vals of 40 seconds at 20% of the short time maximum
exercise capacity, i.e. with a work/recovery ratio of 1:2.
Then patients have a slow down period of two minutes
before completion of the training session. Pulse oxymetry
will be used and oxygen supplementation will be pro-
vided as described above.
If patients cannot sustain exercise intensity because the
heart rate exceeds the limits determined after exercise test-
ing or because of perceived dyspnoea or leg fatigue, phys-
ical therapists will let patients rest for one minute and
then resume exercise. If patients have to rest more than
twice per session, physical therapists will lower the work-
load from 50% of the short time maximum exercise capac-
ity by steps of 10% while the length of intervals remains
constant. They will increase the training load again as pos-
sible for the patient.
In turn, if patients or physical therapists consider the
workload to be too low, physical therapists will increase
workload of the high intensity interval by steps of 10%
until patients and physical therapists consider the work-
load to be appropriate while the length of intervals
remains constant.
Clinical outcome measures
Chronic Respiratory Questionnaire (CRQ)
We will use the CRQ[23] to measure HRQL changes dur-
ing rehabilitation. The CRQ is a widely used disease-spe-
cific instrument to assess symptoms of COPD patients
[24-26] We will use the self-administered German
CRQ.[27,28] with standardised dyspnoea questions.[29]
that we have developed and validated in earlier studies.
Patients will complete the CRQ in the Klinik Barmelweid
at baseline, at the end of the rehabilitation, two and 12
weeks thereafter when they have returned to their home
environment.
HADS (Hospital Anxiety Depression Score)
Affective disorders are common in patients with COPD
and contribute to reduced HRQL[30] The HADS has been
developed to assess symptoms of anxiety and depression
in patients with physical impairment.[31] There are seven
items for each domain (anxiety and depression) with
statements on emotions and emotional situations.
Patients express their agreement with the statements on a
scale from 0 to 3. Domain scores are calculated by sum-
ming up the scores for the seven domains resulting in
scores from 0 (no depression or anxiety) to 21 (depres-
sion or anxiety very likely to be present). Scores ≥  8 indi-
cate that there is an increased probability for the presence
of an affective disorder. We will use the validated self-
administered German version of the HADS.[32] The
HADS will be completed in the Klinik Barmelweid at base-
line, at the end of the rehabilitation, two and 12 weeks
thereafter when they have returned to their home
environment.
Feeling Thermometer (FT)
We will use a validated visual analogue scale, the FT[33],
an increasingly used instrument for a global estimate of
the effect of interventions, including respiratory rehabili-
tation[29,34]. The FT is a visual analogue scale presented
as a thermometer with 100 marked intervals. The worst
(dead = 0) and best (perfect health = 100) health states are
defined anchors and facilitate comparisons between
individuals and groups.[35] We will ask patients to reflect
in their score how they felt in the last 7 days.
The FT will be completed in the Klinik Barmelweid at
baseline, at the end of the rehabilitation, two and 12
weeks thereafter when they have returned to their home
environment.
Six-minute walk test
We will use the six-minute walk test to assess functional
exercise capacity according to established criteria.[36] At
baseline, patients will perform the six-minute walk test
twice one day apart. We will use the results of the second
six-minute walk test because the first test tends to
underestimate exercise capacity due to unfamiliarity with
the test.[36]. At the end of the rehabilitation and two
weeks after completion of rehabilitation programme
patients will perform additional six-minute walk tests
under supervision of physical therapists blinded to group
assignment. In addition, we will use a paperboard with a
modified Borg scale on from 0 to 10 with verbal labels for
0 (no dyspnoea at all), 1–5, 7 and 10 (maximal dyspnoea)
to assess the intensity of perceived dyspnoea at the end of
the six-minute walk test.
Monitoring of exercise sessions
Dyspnoea and leg pain during exercise
In each session, we will use modified Borg scale as
described above to assess the intensity of perceived dysp-
noea and leg pain after five minutes of exercise and at the
end of the exercise sessions.BMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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Subjective experience of exercise
There is no instrument available to assess the subjective
experience of COPD patients with exercise, which is likely
to influence compliance. We have developed a question-
naire using established methodology[37] to assess how
patients experienced the sessions. The questionnaire
(Exercise Tolerance Questionnaire) consists of five ques-
tions addressing the exercise limitation by shortness of
breath and difficulties with breathing, leg fatigue, fatigue
in general and too high exercise load. In addition, one
question asks patients how they experienced the exercise
session in general (from very enjoyable to very unpleas-
ant). The report on questionnaire development will be
published elsewhere.
Adherence to and tolerance of the prescribed cycle ergometer 
exercise
Physical therapists will record for every cycle ergometer
exercise session if patients exercised at all (yes or no), the
performed workload (in Watts), if patients reached the
target workload (in Watts), adjustments of workload and
the requirement for oxygen. We define adherence to exer-
cise as "full adherence" if patients follow at least 12 exer-
cise sessions. We consider the training to be fully tolerated
if patients are able to follow the exercise protocol for at
least 9 exercise sessions for continuous exercise (taking
into consideration the first three exercise session when
patients increase training load up to 70% of maximum
exercise capacity) and for at least 12 exercise sessions for
interval exercise.
Adverse events
Previous trials of respiratory rehabilitation or physical
exercise did not report any adverse events. Nevertheless,
we will record any adverse events such as injuries, cardiac
events or increase of respiratory symptoms as they happen
during the inpatient respiratory rehabilitation.
Cardiopulmonary exercise testing
At baseline and end of the rehabilitation, all patients will
perform an incremental cycle ergometer test to the limit of
tolerance (symptom based) under the supervision of a
senior physician blinded to group assignment. Patients
pedal unloaded for three minutes to warm up at 20 Watts.
Then exercise load is increased by 7.5 Watts per minute
until patients have to stop because of dyspnoea, leg pain,
or criteria for stop testing (atrial or ventricular tachycar-
dia, ischemia, hypoxemia). At the limit of tolerance, we
will draw capillary blood samples to measures lactate con-
centrations and we will set the maximum exercise capacity
expressed by Watts. The upper limit for the heart rate dur-
ing exercise is set as the heart rate measured by the electro-
cardiogram at the maximum exercise capacity.
During testing, we will record gas exchange and ventila-
tory variables form calibrated signals derived from rapidly
responding gas analyzers and a mass flow sensor. We will
record breath by breath the following variables: Pulmo-
nary oxygen uptake, pulmonary CO2 output, minute ven-
tilation, tidal volume and respiratory frequency.
All patients will perform a steep ramp test at the beginning
and end of the rehabilitation programme as described
above.
Additional data to be collected
In order to characterize the patient included in the study,
we will record their age, gender, lung function (FEV1,
FEV1/FVC, diffusion capacity DLCO/VA, weight, height,
smoking status at the beginning and end of rehabilitation
as well as two and 12 weeks afterwards, duration of dis-
ease (time since diagnosis), co-morbidities such as hyper-
tension, heart diseases, endocrine disorders, chronic
rheumatological disorders and psychiatric disorders.
Data analysis
The randomisation code will not be broken (investigators
remain blinded to group assignment and will receive only
codes, such as group 1 and 2) until a draft of the manu-
script has been written. The authors will write two ver-
sions with alternative possible allocation patterns to avoid
bias in the interpretation of the results. This approach is
methodologically rigorous and limits introduction of bias
during the interpretation of the data that some of the
authors might have.[38] We will submit the appropriate
manuscript regardless of the results of unmasking. After
agreement on the final versions of the two articles, we will
break the randomisation code and we will submit the cor-
rect version of the manuscript.
Effectiveness
Our null hypothesis is that high intensity continuous
exercise is of clinically superior effectiveness compared
with interval exercise to improve HRQL (δ  ≥  0.5 in CRQ
domains scores). The alternative hypothesis is that inter-
val exercise is not of clinically inferior effectiveness com-
pared with high intensity continuous exercise.
In the primary analysis, we will calculate the raw differ-
ence and 95% confidence intervals between groups in the
mean follow-up score for the CRQ domains 2 weeks after
completion of the respiratory rehabilitation programme.
In an additional analysis, we will adjust for the base-line
score and the four stratification variables using an analysis
of covariance. We will use independent t-test to compare
the change scores between groups.
We will also use the confidence interval approach as rec-
ommended for equivalence and non-inferiority trials[13]BMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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We will establish non-inferiority of interval exercise if the
point estimate and its 95% confidence interval for differ-
ence between the change scores of the continuous and
interval exercise group is smaller than the a priori deter-
mined boundary of clinical equivalence (see figure 3). If
the 95% confidence intervals lie outside the boundaries of
clinical equivalence we will establish clinical superiority
of one exercise protocol.
Most methodologists and statisticians agree that the
boundaries of equivalence should be defined as the mini-
mal important difference and below the differences
observed in previous trials comparing active to control
treatments.[13,39] The minimal important difference is
"the smallest difference in score in the outcome of interest
that informed patients perceive as important, either bene-
ficial or harmful, and which would lead the clinician to
consider a change in the management"[40]. Therefore, the
minimal important difference of our two main outcome
measures for effectiveness have been established empiri-
cally and are around 0.5 for the CRQ domains scores [41-
44] and 53 meters for the six-minute walk test[45]. A
recent meta-analysis showed that respiratory rehabilita-
tion with physical exercise leads to improvements of 50
meters in the six-minute walk test. Therefore we lower the
boundaries for equivalence to ± 45 meters in order to have
boundaries that are below the differences observed in
previous trials comparing active to control
treatments.[13,39]
We will repeat the analysis with calculations of raw and
adjusted differences for all other clinical and physiologic
outcome measures and test for significant differences
Illustration of the confidence interval approach to interpret results from randomised trials Figure 3
Illustration of the confidence interval approach to interpret results from randomised trials. The horizontal line indicates the dif-
ference between CRQ change scores between study groups. ± 0.5 points represent the predefined boundaries of equivalence. 
If the whole confidence interval is on the right of 0.5 points, interval exercise is not inferior to continuous exercise. If the 
whole confidence interval is within boundaries the two exercise protocols are of clinically equivalent effectiveness (upper three 
confidence intervals). Note that there can be a statistically significant difference between study groups but without any clinical 
relevance.
Difference between study groups
(Mean CRQ score continuous exercise group minus 
mean CRQ score interval exercise group)
0 Difference = -0.5
patients perceive interval 
exercise as superior
Difference = 0.5
patients perceive continuous 
exercise as superior
Clinical equivalence and statistically 
not significant difference
Clinical equivalence and continuous 
exercise statistically superior to interval 
exercise
Interval exercise statistically and maybe 
clinically superior to continuous exercise 
Statistically not significant difference 
and sample size too small to show 
equivalence
Continuous exercise statistically and 
clinically superior to interval exercise 
Point estimate and 95% 
confidence interval
Difference between study groups
(Mean CRQ score continuous exercise group minus 
mean CRQ score interval exercise group)
0 Difference = -0.5
patients perceive interval 
exercise as superior
Difference = 0.5
patients perceive continuous 
exercise as superior
Clinical equivalence and statistically 
not significant difference
Clinical equivalence and continuous 
exercise statistically superior to interval 
exercise
Interval exercise statistically and maybe 
clinically superior to continuous exercise 
Statistically not significant difference 
and sample size too small to show 
equivalence
Continuous exercise statistically and 
clinically superior to interval exercise 
Point estimate and 95% 
confidence intervalBMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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between groups using independent t-test if data are dis-
tributed normally.
We will use both intention to treat and per protocol anal-
ysis to show equivalence in either case as recommended
by others[13,39,46,47]
Exercise tolerance
Our null hypothesis is that patients equally experience
high intensity continuous exercise and interval exercise as
measured by the Exercise Tolerance Questionnaire. The
alternative hypothesis is that interval exercise is associated
with the experience of less limiting symptoms compared
with high intensity continuous exercise.
We will use independent t-tests to compare the measures
for exercise tolerance (Exercise Tolerance Questionnaire,
Borg scales for dyspnoea and leg pain) between groups.
Again, we will assess the raw differences between groups
in the primary analysis and adjust for baseline scores and
the four stratification variables in the additional analysis.
Confounder variables and effect modifiers
Factors, which interfere with outcome measures, can dis-
tort the results if unevenly distributed between study
groups. We use three approaches to control for confound-
ers: First, we use randomisation to allocate patients. Sec-
ond, we strengthen the randomisation using a
computerised minimisation procedure with factors that
are likely to influence the outcome measures (exercise
capacity, pulmonary state and presence and absence of
affective disorders). Third, we will collect a number of var-
iables at baseline (age, gender, lung function, time since
diagnosis, cumulative dose of oral steroids in previous
three months, medication, cardiovascular, musculoskelet-
tal and endocrine co-morbidities) that may modify the
effect of exercise. We will compare the distribution of
these potential effect modifiers between groups and statis-
tically assess their influence on the outcome measures
with multiple linear regression models.
Sample size
For calculating the required sample size, we use the for-
mula for comparison of 2 means: n = [A + B]2 * 2 * SD2/
DIFF2, where n = the sample size required in each group
(double for total sample), SD = standard deviation of the
outcome variable, DIFF = size of desired difference
between groups. A and B depend on the desired signifi-
cance level and desired power, respectively.
We base our sample size calculations on the CRQ. We
used empirical data from our previous trial.[27], where we
applied similar inclusion criteria for patients with COPD
undergoing respiratory rehabilitation, to estimate varia-
bility of the CRQ (standard deviation of the CRQ domain
scores between 0.8 and 1.2). A clinically sensible way to
determine the size of desired difference between groups
(DIFF in formula above) is based on the minimal impor-
tant difference (0.5 on the scale from 1 to 7 for the
CRQ)[41-43,48] A sample size of 44 patients in each
group will allow showing a difference of 0.5 in CRQ
scores between the groups, assuming a standard deviation
of 0.8, with a power of 90% at a significance level of 5%
(one-sided). Assuming a drop out rate of 15%.[27], the
total minimal sample size increases to 104. This sample
size will also allow detecting a difference of 45 meters in
the six-minute walking test scores between the two treat-
ment groups with a power of 95% at a significance level of
5% (one-sided) assuming a drop out rate of 15%.
A priori sample size calculations usually provide only
rough estimates. Therefore, we will recalculate sample size
during the study when we have the data for 30 patients in
each group. To this end, we will re-assess the standard
deviation of the outcome variables and, if necessary,
adjust the sample size accordingly (without breaking the
randomisation code).
Data collection and quality control
We will implemented a series of measures to ensure high
data quality.
1. Site investigators will collect the data using standard-
ized forms. All data will be collected and entered into a
single database in the Horten Centre by one investigator.
A second investigator will validate completeness and
accuracy of data extraction by checking 20% of extracted
patient data.
2. Checklists with all the data to be collected will be pro-
vided for physical therapists and physicians.
3. Teaching sessions will be held regularly for physical
therapists and physicians involved in data collection aim-
ing at robust data collection.
4. Investigators meetings will be held monthly, or more
frequently if needed, to discuss recruitment of patients,
problems in conducting the study, acquisition of data, to
check for consistency and completeness of data and for
interim analyses.
5. E-mail will serve as the first line of non-urgent commu-
nication between research team members.
6. Monthly reports will be prepared by the principal inves-
tigator that will include the number of patients recruited,
stage of follow up for each patient, notification regarding
missing patient data and queries from data received.BMC Pulmonary Medicine 2004, 4:5 http://www.biomedcentral.com/1471-2466/4/5
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Discussion
In the last 30 years, researchers made great efforts to study
the effectiveness of respiratory rehabilitation compared to
usual care. The meta-analyses of a recent systematic
review[3] showed that respiratory rehabilitation with
physical exercise leads to clinically significant improve-
ments of HRQL as well as to significant improvements of
functional and maximum exercise capacity.
Research in respiratory rehabilitation should now focus
on the evaluation of different exercise protocols. When an
effective treatment such as respiratory rehabilitation is
available, patients and clinicians are not confronted with
the decision whether to start treatment or not, but with
the decision on the most appropriate treatment. There-
fore, clinicians need evidence from pragmatic randomised
controlled trials directly comparing different exercise pro-
tocols at issue rather than evidence from (explanatory) tri-
als comparing exercise with no exercise or usual care.[49]
The proposed pragmatic trial will therefore provide
important and needed guidance for decision-making in
respiratory rehabilitation, in particular for those COPD
patients who are severely impaired and initiate respiratory
rehabilitation programmes.
The evidence generated in the proposed clinical trial will
also be relevant for the scientific community. From the
1970s up to the mid-1990s most investigators conducted
explanatory clinical trials in order to better understand
how and why physical exercise is effective in patients with
COPD. After the recognition of its effectiveness the debate
on the optimal exercise modality arose[6]. However, only
few pragmatic trials have been conducted so far to
advance the understanding of the relative benefit and
downsides of different exercise protocols. With the pro-
posed trial, we compare two clinically relevant interven-
tions with the use of a clinical trial design that is useful for
clinical decision making. Such trials are currently needed
to gain consensus on the optimal exercise protocol.
There is a need for randomised controlled trials to explore
which exercise protocols are most effective for COPD
patients. Another topic that has received little attention in
respiratory rehabilitation trials so far is compliance to and
subjective experience of physical exercise[9] Exercise pro-
tocols and adherence to it have not been described in
detail in published studies[3] and therefore very little is
known about the tolerance of different training modali-
ties. This is despite the fact that physical exercise has long
been considered unfeasible in patients with COPD.
Beside the paucity of data on the effectiveness and toler-
ance of different exercise protocols, there is also a need for
trials that are methodologically sound and rigorous. Most
of the studies on exercise or respiratory rehabilitation in
patients with COPD did not report on details of exercise
tests and protocols. In addition, study design related
issues that introduce bias such as description of the ran-
domisation procedure, concealment of allocation, sample
size calculations or blinding have not been addressed fre-
quently. Therefore, we try to use strong epidemiological
methods to minimize bias in our trial.
Our study could make an important contribution to the
understanding of physical exercise in patients with COPD
and have a significant impact on the structure of respira-
tory rehabilitation and exercise programmes.
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